Cargando…

A case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine: a case report

BACKGROUND: More than 4 billion doses of the Coronavirus disease (COVID-19) vaccine have been administered worldwide but the relationship between the different vaccines and the development of renal disease is unknown. We present a case of tubulointerstitial nephritis following administration of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Samuel B. M., Holwill, Stephen D. J., Clissold, Rhian L., Bingham, Coralie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013276/
https://www.ncbi.nlm.nih.gov/pubmed/36918813
http://dx.doi.org/10.1186/s12882-023-03089-2
_version_ 1784906779325366272
author Williams, Samuel B. M.
Holwill, Stephen D. J.
Clissold, Rhian L.
Bingham, Coralie
author_facet Williams, Samuel B. M.
Holwill, Stephen D. J.
Clissold, Rhian L.
Bingham, Coralie
author_sort Williams, Samuel B. M.
collection PubMed
description BACKGROUND: More than 4 billion doses of the Coronavirus disease (COVID-19) vaccine have been administered worldwide but the relationship between the different vaccines and the development of renal disease is unknown. We present a case of tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine. CASE PRESENTATION: A previously fit and well 51-year-old female presented on 27th May 2021 with a one-month history of weight loss, fatigue, nausea, and a metallic taste. She had an acute kidney injury with a creatinine of 484 umol/L. She was on no regular medications and denied taking any over-the-counter or alternative medicines. She had received her first dose of the Oxford-AstraZeneca vaccine on 23rd March 2021 and her second dose on 20th May 2021. A renal biopsy was performed the following day. The 19 glomeruli appeared normal to light microscopy but the tubulointerstitial compartment contained a dense inflammatory infiltrate including many eosinophils. There was widespread acute tubular injury with tubulitis, but no established or longstanding atrophy. A diagnosis was made of an acute tubulointerstitial nephritis. She was commenced on oral prednisolone and her renal function improved. She did not require renal replacement therapy at any time. CONCLUSIONS: To our knowledge, this was the first described case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine, although a number of cases have emerged more recently. In our case the patient was very fit and well, had no previous past medical history and had not taken any recent prescribed, over-the-counter or alternative medications. The absence of these provoking factors in our case makes the vaccine the most likely explanation for the development of tubulointerstitial nephritis although the pathophysiology behind this remains unknown. Given the unprecedented number of vaccinations being delivered around the world, nephrologists should be aware of this possible link although more research into the topic is required.
format Online
Article
Text
id pubmed-10013276
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100132762023-03-14 A case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine: a case report Williams, Samuel B. M. Holwill, Stephen D. J. Clissold, Rhian L. Bingham, Coralie BMC Nephrol Case Report BACKGROUND: More than 4 billion doses of the Coronavirus disease (COVID-19) vaccine have been administered worldwide but the relationship between the different vaccines and the development of renal disease is unknown. We present a case of tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine. CASE PRESENTATION: A previously fit and well 51-year-old female presented on 27th May 2021 with a one-month history of weight loss, fatigue, nausea, and a metallic taste. She had an acute kidney injury with a creatinine of 484 umol/L. She was on no regular medications and denied taking any over-the-counter or alternative medicines. She had received her first dose of the Oxford-AstraZeneca vaccine on 23rd March 2021 and her second dose on 20th May 2021. A renal biopsy was performed the following day. The 19 glomeruli appeared normal to light microscopy but the tubulointerstitial compartment contained a dense inflammatory infiltrate including many eosinophils. There was widespread acute tubular injury with tubulitis, but no established or longstanding atrophy. A diagnosis was made of an acute tubulointerstitial nephritis. She was commenced on oral prednisolone and her renal function improved. She did not require renal replacement therapy at any time. CONCLUSIONS: To our knowledge, this was the first described case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine, although a number of cases have emerged more recently. In our case the patient was very fit and well, had no previous past medical history and had not taken any recent prescribed, over-the-counter or alternative medications. The absence of these provoking factors in our case makes the vaccine the most likely explanation for the development of tubulointerstitial nephritis although the pathophysiology behind this remains unknown. Given the unprecedented number of vaccinations being delivered around the world, nephrologists should be aware of this possible link although more research into the topic is required. BioMed Central 2023-03-14 /pmc/articles/PMC10013276/ /pubmed/36918813 http://dx.doi.org/10.1186/s12882-023-03089-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Williams, Samuel B. M.
Holwill, Stephen D. J.
Clissold, Rhian L.
Bingham, Coralie
A case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine: a case report
title A case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine: a case report
title_full A case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine: a case report
title_fullStr A case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine: a case report
title_full_unstemmed A case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine: a case report
title_short A case of acute tubulointerstitial nephritis following administration of the Oxford-AstraZeneca COVID-19 vaccine: a case report
title_sort case of acute tubulointerstitial nephritis following administration of the oxford-astrazeneca covid-19 vaccine: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013276/
https://www.ncbi.nlm.nih.gov/pubmed/36918813
http://dx.doi.org/10.1186/s12882-023-03089-2
work_keys_str_mv AT williamssamuelbm acaseofacutetubulointerstitialnephritisfollowingadministrationoftheoxfordastrazenecacovid19vaccineacasereport
AT holwillstephendj acaseofacutetubulointerstitialnephritisfollowingadministrationoftheoxfordastrazenecacovid19vaccineacasereport
AT clissoldrhianl acaseofacutetubulointerstitialnephritisfollowingadministrationoftheoxfordastrazenecacovid19vaccineacasereport
AT binghamcoralie acaseofacutetubulointerstitialnephritisfollowingadministrationoftheoxfordastrazenecacovid19vaccineacasereport
AT williamssamuelbm caseofacutetubulointerstitialnephritisfollowingadministrationoftheoxfordastrazenecacovid19vaccineacasereport
AT holwillstephendj caseofacutetubulointerstitialnephritisfollowingadministrationoftheoxfordastrazenecacovid19vaccineacasereport
AT clissoldrhianl caseofacutetubulointerstitialnephritisfollowingadministrationoftheoxfordastrazenecacovid19vaccineacasereport
AT binghamcoralie caseofacutetubulointerstitialnephritisfollowingadministrationoftheoxfordastrazenecacovid19vaccineacasereport